Lilly’s Sigilon buyout came more than a year after the diabetes cell therapy partner first broached the idea

Kyle LaHucik

Senior Reporter

Well before its sale to Eli Lilly, Sigilon Therapeutics contemplated an exit to its diabetes partner in late 2021, after the cell therapy biotech pruned its pipeline. But the Big Pharma didn’t bite, according to new documents filed with the SEC.

Once a high-flying biotech out of Flagship Pioneering, Sigilon and Lilly teamed up on a diabetes cell therapy program in 2018, and the Boston-area biotech then went public in December 2020. But it would end up running into multiple setbacks before agreeing to the up to $309 million deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Lilly’s Sigilon buyout came more than a year after the diabetes cell therapy partner first broached the idea

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Acelyrin's founding CEO steps down, company scraps earnings call

Takeda to revamp in multiyear quest, pivots CAR-NK therapy from cancer to autoimmune

Lawmakers consider limiting how long existing WuXi contracts can continue

Novo Nordisk sees more to GLP-1's future in $600M pact with Flagship's Metaphore

CytomX shares plummet as Amgen-partnered cancer drug yields jumbled Phase 1 data

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Lil­ly’s Sig­ilon buy­out came more than a year af­ter the di­a­betes cell ther­a­py part­ner first broached the idea

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Ace­lyrin's found­ing CEO steps down, com­pa­ny scraps earn­ings call

Take­da to re­vamp in mul­ti­year quest, piv­ots CAR-NK ther­a­py from can­cer to au­toim­mune

Law­mak­ers con­sid­er lim­it­ing how long ex­ist­ing WuXi con­tracts can con­tin­ue

No­vo Nordisk sees more to GLP-1's fu­ture in $600M pact with Flag­ship's Metaphore

Cy­tomX shares plum­met as Am­gen-part­nered can­cer drug yields jum­bled Phase 1 da­ta

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Lilly’s Sigilon buyout came more than a year after the diabetes cell therapy partner first broached the idea

Acelyrin's founding CEO steps down, company scraps earnings call

Takeda to revamp in multiyear quest, pivots CAR-NK therapy from cancer to autoimmune

Lawmakers consider limiting how long existing WuXi contracts can continue

Novo Nordisk sees more to GLP-1's future in $600M pact with Flagship's Metaphore

CytomX shares plummet as Amgen-partnered cancer drug yields jumbled Phase 1 data

Medical Affairs: The Critical Link Between Science, Physicians and Patients